-transparent.png){kind=logo}
Three groups of children with acute lymphoblastic leukemia (ALL) were treated with intermittent cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). Group A (no prior relapse) and Group B (prior single-agent relapse) received COAP after 12 months on another chemotherapy regimen. Children in Group C (prior relapse on multiagent regimens) received COAP following A-COAP (asparaginase plus COAP) reinduction. Median disease-free survival after beginning COAP was not reached for Group A, but was only 7 months for Groups B and C. As of November 1976, there were 8 of 15 Group A patients, 1 of 12 Group B patients, and 1 of 28 Group C patients who had remained disease-free from 38 to 60 (median 54.5) months and were off chemotherapy. COAP has activity in childhood ALL. However, effectiveness is markedly diminished in patients with prior bone marrow relapse.
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
January 1981,
Medical and pediatric oncology,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
August 1972,
Cancer chemotherapy reports,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
September 1978,
Cancer treatment reports,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
January 1991,
Haematologica,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
January 1984,
Sangre,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
February 1995,
Annals of hematology,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
January 1979,
Medical and pediatric oncology,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
January 1978,
Medical and pediatric oncology,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
June 1981,
Cancer,
S E Sallan, and
B M Camitta, and
D M Chan, and
D Traggis, and
N Jaffe
October 1975,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
